Spyre Therapeutics, Inc. financial data

Symbol
SYRE on Nasdaq
Location
Waltham, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 04 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 874% % -20%
Debt-to-equity 16% % -46%
Return On Equity -31% % 62%
Return On Assets -27% % 47%
Operating Margin -39429% % -480%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 77,592,130 shares 51%
Common Stock, Shares, Outstanding 60,471,793 shares 18%
Entity Public Float $1,100,000,000 USD 4098%
Common Stock, Value, Issued $13,000 USD 8.3%
Weighted Average Number of Shares Outstanding, Basic 50,889,433 shares 1085%
Weighted Average Number of Shares Outstanding, Diluted 50,889,433 shares 1085%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD -100%
General and Administrative Expense $46,146,000 USD -6%
Operating Income (Loss) $213,643,000 USD -11%
Nonoperating Income (Expense) $64,660,000 USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $148,983,000 USD 31%
Income Tax Expense (Benefit) $14,000 USD -128%
Net Income (Loss) Attributable to Parent $148,969,000 USD 31%
Earnings Per Share, Basic -19 USD/shares -219%
Earnings Per Share, Diluted -19 USD/shares -219%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $64,897,000 USD -9.3%
Cash, Cash Equivalents, and Short-term Investments $603,100,000 USD 78%
Assets, Current $504,604,000 USD 20%
Other Assets, Noncurrent $0 USD -100%
Assets $504,604,000 USD 20%
Liabilities, Current $46,274,000 USD -20%
Liabilities $49,504,000 USD -47%
Accumulated Other Comprehensive Income (Loss), Net of Tax $791,000 USD -46%
Retained Earnings (Accumulated Deficit) $1,065,105,000 USD -16%
Stockholders' Equity Attributable to Parent $455,100,000 USD 39%
Liabilities and Equity $504,604,000 USD 20%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $40,994,000 USD -44%
Net Cash Provided by (Used in) Financing Activities $125,000 USD -100%
Net Cash Provided by (Used in) Investing Activities $61,000 USD 100%
Common Stock, Shares Authorized 400,000,000 shares 0%
Common Stock, Shares, Issued 60,471,793 shares 18%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $40,930,000 USD -206%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $64,897,000 USD -9.3%
Deferred Tax Assets, Valuation Allowance $162,929,000 USD 30%
Deferred Tax Assets, Gross $163,021,000 USD 30%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $149,635,000 USD 30%
Deferred Tax Assets, Operating Loss Carryforwards $87,321,000 USD 17%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 14%
Unrecognized Tax Benefits $0 USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $0 USD -100%
Share-based Payment Arrangement, Expense $9,566,000 USD -27%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%